Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipatasertib plus abiraterone vs placebo plus abiraterone in metastatic castration-resistant prostate cancer
jRCT2080223518Phase 3Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Apr 2017
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in metastatic castration-resistant prostate cancer (mCRPC) comparing Ipatasertib combination arm with Placebo combination arm (2 arms). Started Apr 2017; status: completed.
02
Drugs
ipatasertib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on jRCT2080223518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223518.